Global tissue engineering market is expected to reach USD 11.53
billion by 2022, according to a new report by Grand View Research, Inc. The
demand for tissue engineering is expected to upsurge owing to the shift of
focus from stem cell therapies to immunocelluar therapies. Moreover, companies
such as Caladrius and Celyad changed their names from Cardio3 Bio NeoStem
respectively to reflect their focus on immunotherapies.
The market is also experiencing
industry-academia collaboration to make the commercialization of viable cell
therapies possible. In July 2015, Fate Therapeutics, Inc. collaborated with
theUniversity of Minnesota to research on Natural Killer (NK) therapeutics,
which can detectand kill the malignant cells. The research is expected to
accelerate with the use of programmed therapeutics by Fate Therapeutics.
With the technological
advancements, researchers are working upon custom-made body parts with the aid
of biomaterials and bio 3D printing. The demand for orthopedic implants is
continuously growing; however, there is a gap between the demand and supply. To
address such issues, researchers are experimenting with ways to find out
alternatives, which use in-vitro testing and humane substitutes.
Investigators are working on ways
to develop 3D printed organs, which can offer low-cost implantation. This step
can revolutionize the 3D printing industry, but many hurdles such as donor
availability, technologically-advanced 3D printers, and financial barriers have
to be overcome. For instance, the cost of 3D printing ranges from USD 100 for
tracheal split to USD 40,000 for nose bio-printing. Thus, there is a need for
scientists and researchers to work on this multidisciplinary aspect of
bio-printing.
Request to Sample of
This Report @ http://www.grandviewresearch.com/industry-analysis/tissue-engineering-and-regeneration-industry
Further key findings
from the report suggest:
·
Orthopedics
dominated the application segment in 2014 owing to the continuous launch of new
products and research funding. In February 2016, Geistlich Pharma launched a
range of bone harvesting instrument for the efficient collection of autogenous
bone. Implant of only autogenous bone causes resorption and volume depletion.
With the use of Geistlich Bio-Oss-pioneered technology, the volume as well as
properties of bone is restored.
·
North America was
the largest regional market with a revenue share estimated at over 50% owing to
the various mergers and acquisitions along with huge funds available for
research. In March 2016, Zimmer Bimet acquired Ortho Transmission for its
pioneered technology, which could restore limb amputee patients.
·
By acquiring the
skeletal implant technology, Zimmer can efficiently work on its current project
received by the U.S. Department of Defense to develop external prosthetic
limbs. Moreover, in February 2016, Canadian scientists from the University of
Toronto’s dentistry pioneered a 3D printed method for absorbable
bone-implant.
·
Europe was the
second largest market in 2014, due to the amount of research and the funding
received by the research universities. For instance, in June 2014, the European
Union funded the VascuBone project to offer an alternative to bone grafts. The
University Hospital of Wurzburg developed a toolbox to bring together the
solutions required to offer ideal therapy to patients.
·
Countries in
Europe are also expanding their research knowledge by partnering with other
countries’ research firms. For instance, in March 2013, Johannes Gutenberg
University Mainz and Chinese Academy of Sciences formed the Chinese-German
Joint Center for Bio-Inspired Materials. The scientists will work on using
marine animals for osteoporosis medication.
·
Asia Pacific is
the fastest growing regional segment on the account of increasing interest of
foreign players to establish their facilities in economically developed
countries such as India and Japan. In August 2013, the Japan Health Ministry
approved the clinical trial of the developing induced pluriponent stem (iPS)
cells for blindness. The cells are morphed into retinal cells and then given to
six patients with macular degeneration (AMD).
·
India is in an
ascent stage of research and trying to develop in the tissue engineering area.
In February 2016, India Biotechnology Event was held, where experts blamed the
snail pace of development to the tedious and long approval process. The
suggestion was to adopt Japan’s new executed law, where the sponsor has to
demonstrate only the safety and efficacy studies of the device.
·
Key players of
this market includeMedtronic, Inc., Zimmer Biomet, Acelity, Acell, Inc.,
Athersys, Inc., Organogenesis, Inc., Stryker Corporation, Tissue Regenix Group
Plc, RTI surgical, Inc., and ReproCell, Inc.
·
Industry
contributors are establishing their market presence by acquiring other
companies or by launching new products in the market. In November 2015,
ReproCell, Inc. acquired Biopta to leverage on Bipota’s clinical network in the
U.S and the UK. Biopta has worked on around 500 new medicines and has
partnerships with Scottish Enterprise and the NHS. Moreover, in February 2016,
RTI Surgical, Inc. received exclusive licensing rights by RTI Surgical, Inc.
Through this, RTI can access the OPM’s OsteoFab technology for spinal
procedures.
To Get Sample Copy of Report visit
@ http://www.grandviewresearch.com/industry-analysis/tissue-engineering-and-regeneration-industry/request
About Grand View
Research
Grand View Research, Inc. is a U.S. based market research and
consulting company, registered in the State of California and headquartered in
San Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed
business decisions, the company offers market intelligence studies ensuring
relevant and fact-based research across a range of industries including
technology, chemicals, materials, healthcare and energy.
For More Information,
Visit Grand
View Research
Contact:
Sherry James
Corporate Sales Specialist, U.S.A.
Grand View Research, Inc.
United States
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
No comments:
Post a Comment